Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent

Aileron Therapeutics Inc ALRN presented new clinical data at the European Society of Medical Oncology (ESMO21) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.
Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells.
The Company presented final results from Phase 1b trial of ALRN-6924 in patients with small-cell lung cancer (SCLC) receiving second-line topotecan treatment.
The data demonstrated ALRN-6924's 'triple-play efficacy' for reducing neutropenia, thrombocytopenia, anemia, and a reduction of platelet and red blood cell transfusions compared to historical controls.
While chemoprotection effects were observed across all ALRN-6924 dose levels, the 0.3 mg/kg ALRN 6924 dose level given 24 hours before topotecan demonstrated the most robust chemoprotection results.
None of the patients treated at the 0.3 mg/kg 24 hour ALRN-6924 dose level had a related serious adverse event (SAE).
At the 0.3 mg/kg 24 hour ALRN-6924 dose level, one patient required a red blood cell transfusion and a platelet transfusion.
In the topotecan plus placebo arm of a third-party Phase 2 trial, in SCLC patients receiving topotecan (N=28), 41% and 31% received red blood cell and platelet transfusions, respectively.
Price Action: ALRN stock is down 6.52% at $1.08 during the market session on the last check Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga